Earnings: Regeneron Pharmaceuticals (REGN) Q1 profit falls as revenues drop 31%

[ad_1] Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) on Monday reported a decline in fourth-quarter earnings and adjusted earnings. Total revenue fell 31% year over year to $3.41 billion in the three months ending December 2022. However, excluding REGEN-COV and Ronapreve,…





